Category: Biotech

PEGylated Proteins Market: Global Industry Analysis, Size, Share,…

PEGylated Proteins Market: Overview PEGylation is the process through which strands of the PEG polymer are attached to molecules most typically proteins. Through PEGylation, increased drug stability, reduced dosage frequency, improved drug solubility, extended circulating life, increased efficiency with potentially reduced toxicity and enhanced protection from proteolytic degradation can be obtained.

Merck profit soars on new drugs, expects better 2017

Merck CEO Kenneth Frazier on Thursday said he’s encouraged by an initial meeting he and other pharmaceutical executives had Tuesday with Trump, who has said drugmakers have been The pharmaceutical industry has come under fire in recent months over soaring drug prices, which have been blasted by patients, doctors, politicians and others. Drug companies and investors have been alternatively worried that the Trump administration and Congress will move to reduce prices, and cheered by hopes that they will help them increase profits by reducing taxes and reducing regulations so they can bring new drugs to market faster.

View Press Release

The Summit aims to showcase innovative organizations and how they are responding to changes occurring in the cancer care marketplace. “Today’s community oncology practices face many decisions and challenges, from new reimbursement structures to care models and technologies,” said Randy Hyun, senior vice president and general manager, Provider Solutions, McKesson Specialty Health.

Merck 2017 forecast eases concerns over royalty payments, dollar

Merck & Co Inc reported better-than-expected U.S. quarterly sales for its key cancer drug, Keytruda, and forecast largely in-line 2017 results, which some analysts said allayed concerns over the impact of a strong dollar and royalty payments. The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016.

Global Auto-Injector Market is Expected to Grow at CAGR 18% and USD 2.9 Billion By 2022

Auto-Injector Device Market Expected To Grow At the CAGR of ~18%, Auto-Injector Market Size Is Expected To Increase by USD 2.9 Billion by the End of 2022 Key Players – SHL Group , Jiangsu Delfu medical device Co., Ltd , Becton, Dickinson and Company , Novartis International AG , Pfizer Inc., Ypsomed Holding AG , Unilife Corporation and Owen Mumford” PUNE, MAHARASTRA, INDIA, February 1, 2017 / EINPresswire.com / — Market Highlights Auto-Injector Market has been evaluated to be rapidly growing and expected to maintain this growth rate. Moreover, there is a huge possibility that the market will grow further in future.

Roche Sees Sales Boost in 2017 With New Lung Drug on U.S. Market

Roche Holding AG pointed toward rising sales this year as its new cancer immune therapy Tecentriq gains wider use for lung tumors. Revenue will probably rise by a low to mid-single digit percentage at constant exchange rates, the same pace as earnings per share excluding some items, the Basel, Switzerland-based company said in a statement Wednesday.

Pfizer Seeks Deals as Generic Versions Hurts Older Drugs’ Sales

Pfizer Inc. expects more generic competition for its established drugs in 2017, and the company’s deal-making to gain products may continue to thrive. After posting fourth-quarter earnings and a forecast that were short of analysts’ estimates, New York-based Pfizer said it would continue to pursue deals, regardless of their size, as long as they create shareholder value.

Dow 30 Earnings: Pfizer Fourth Quarter 2016

… quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company’s Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of …

What Will You Hear on Pfizer’s Fourth-Quarter Call Tuesday?

What’s likely to be at the top of investors’ minds during Pfizer’s fourth-quarter conference call Tuesday morning? How about Pfizer’s plans to overcome oncoming competition involving several important products while navigating what remains a difficult pricing environment? Clues from CEO Ian Read and the management team about the company’s capital deployment plans ought to be of high interest, too. In the wake of continued speculation around the sale of its consumer business, which operates as part of its Innovative Health segment and is home to the Chapstick and Advil brands, potential strategic M&A and divestitures could make up for slowing revenue growth seen across existing therapies.

European agency will review BioCryst’s flu drug

BioCryst Pharmaceuticals Inc., maker of the flu drug Rapivab, announced Monday that the European Medicines Agency will review its drug for the treatment of flu symptoms in adults. The London-based overseer of drugs sold in the European Union will issue a decision within 210 days on whether to allow the sale of Rapivab in the EU’s 28 member states and Norway and Iceland, a market of more than 500 million consumers.

BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency

BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today that the European Medicines Agency has accepted the filing of its peramivir Marketing Authorization Application for treatment of symptoms typical of influenza in adults 18 years and older. The acceptance of the MAA begins the review process by the EMA under the centralized licensing procedure for all 28 member states of the European Union, Norway and Iceland.

CytoDyn Strengthens Executive Management With Appointment of Anthony…

CytoDyn Inc. , a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, announces the appointment of Anthony D. Caracciolo as Executive Chairman of CytoDyn effective immediately. In this new capacity, Mr. Caracciolo will assume an active leadership role in the Company’s strategic planning, business development and operations.

Novartis Signals Growing Ambitions for CAR-T Cancer Treatments

Novartis AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumor-ridden patients. Europe’s second-biggest drugmaker is planning to test its CAR-T treatments — which involve extracting immune cells and genetically engineering them to hunt and kill cancer cells before returning them into the patient’s body — on lethal cancers of the brain, pancreas, colon, ovary and lung.

3 Biotech Stocks I’d Buy Right Now

Despite the sway of political uncertainty for the biotechnology industry at the moment, these three stocks look like great buys right now. Conflicting statements from the Trump administration have made owning biotech stocks feel like a roller-coaster ride in recent weeks, but there are a few stocks I’d happily buy and hold despite the sway of political uncertainty.

Flu Hospitalizations, Deaths Increasing: CDC

Although this year’s flu season appears to be an average one so far, more hospitalizations are being reported and deaths are increasing, federal health officials reported Friday. And it will be several weeks before the season peaks, said Lynnette Brammer, an epidemiologist with the U.S. Centers for Disease Control and Prevention.

Slim’s America Movil reports surprise 4th-qtr loss

Mexican telecoms company America Movil on Thursday said it swung to an almost 6 billion peso net loss in the fourth quarter. ), which is controlled by the family of billionaire Carlos Slim, said the 5.972 billion peso loss compared to a net profit of 15.663 billion pesos in the year-earlier quarter.

Newer Hepatitis C Drugs May Pose Health Risks

Jan. 25, 2017 — Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported.

Health Highlights: Jan. 25, 2017

Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported.

OHSU’s HIV vaccine technology acquired by Bay Area biotech

A San Francisco-based biotech company has acquired vaccine research by Oregon Health & Science University scientists, marking a critical step toward commercialization of a promising HIV vaccine. The deal involves the startup Vir Biotechnology Inc. buying TomegaVax Inc., an OHSU spinoff that holds the rights to the vaccine technology developed by Dr. Louis Picker and Klaus Frueh at OHSU’s Vaccine and Gene Therapy Institute in Beaverton.

FDA rejection of Mezzion’s marketing application for ED candidate…

Korean biotech Mezzion Pharma blames Dr. Reddy’s Laboratories for the FDA’s rejection of its New Drug Application seeking approval of udenafil for the treatment of erectile dysfunction and intends to litigate to recover alleged damages. The company says RDY’s “misconduct” related to cGMP deficiencies was the sole reason for the failed submission.

MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that the medical journal Neuropsychopharmacology has published a new article on MN-166 written by Dr. Lara Ray and colleagues at the University of California, Los Angeles.  The article reports that MN-166 was associated with mood improvements on the stress- and alcohol-cue exposures, as well as reductions in overall craving, depression and anxiety for alcohol in subjects diagnosed with alcohol use disorder .  Moreover, in the subjects that had higher depressive symptomatology, MN-166 reduced the stimulant and mood-altering effects of alcohol compared to placebo.

US: Andrew Wakefield, vaccine skeptic, attends inaugural ball

Controversial vaccine skeptic Andrew Wakefieldattended one of President Trump’s inaugural balls late Friday, prompting a flood of mostly negative reaction on social media, with many commenters raising concerns that his discredited ideas will gain traction in the new administration. Wakefield, who helped launch the anti-vaccine movement with a fraudulent study linking vaccines to autism, posted a Periscope video from one of the balls, calling for an overhaul of the Centers for Disease Control and Prevention.

Report of Severe Adverse Effects of MS Drug Alemtuzumab

The multiple sclerosis therapy alemtuzumab–marketed in the United States as Lemtrada –may trigger severe, unpredictable adverse effects, according to German researchers. Writing in Lancet Neurology , the scientists report on two patients in whom the infusion of alemtuzumab significantly worsened symptoms.

Bristol-Myers Squibb stock sinks 7.2% after it says it won’t pursue…

The company said the decision was made “based on a review of the data available at this time,” and said it would say no more “in order to protect the integrity of ongoing registrational studies.” Leerink analyst Seamus Fernandez said the development was a “clear setback for BMY,” especially given a fall approval by rival drugmaker Merck in first-line lung cancer.